Litcius/Paper detail

Tumor-selective catalytic nanomedicine by nanocatalyst delivery

Minfeng Huo, Liying Wang, Yu Chen, Jianlin Shi

2017Nature Communications1,337 citationsDOIOpen Access PDF

Abstract

Abstract Tumor cells metabolize in distinct pathways compared with most normal tissue cells. The resulting tumor microenvironment would provide characteristic physiochemical conditions for selective tumor modalities. Here we introduce a concept of sequential catalytic nanomedicine for efficient tumor therapy by designing and delivering biocompatible nanocatalysts into tumor sites. Natural glucose oxidase (GOD, enzyme catalyst) and ultrasmall Fe 3 O 4 nanoparticles (inorganic nanozyme, Fenton reaction catalyst) have been integrated into the large pore-sized and biodegradable dendritic silica nanoparticles to fabricate the sequential nanocatalyst. GOD in sequential nanocatalyst could effectively deplete glucose in tumor cells, and meanwhile produce a considerable amount of H 2 O 2 for subsequent Fenton-like reaction catalyzed by Fe 3 O 4 nanoparticles in response to mild acidic tumor microenvironment. Highly toxic hydroxyl radicals are generated through these sequential catalytic reactions to trigger the apoptosis and death of tumor cells. The current work manifests a proof of concept of catalytic nanomedicine by approaching selectivity and efficiency concurrently for tumor therapeutics.

Topics & Concepts

Tumor microenvironmentNanomedicineCatalysisNanomaterial-based catalystGlucose oxidaseNanoparticleChemistryMicrovesiclesCancer cellNanotechnologyFenton reactionCancer researchCombinatorial chemistryTumor cellsBiochemistryEnzymeMaterials scienceCancerBiologymicroRNAGeneGeneticsNanoplatforms for cancer theranosticsAdvanced Nanomaterials in CatalysisNanoparticle-Based Drug Delivery
Tumor-selective catalytic nanomedicine by nanocatalyst delivery | Litcius